Ultimately it looks like two major drug companies are getting what they both think they need. After months of posturing, Sanofi-Aventis (NYSE:SNY) and Genzyme (Nasdaq:GENZ) found common ground on the value and structure of a deal, and Genzyme will become part of Sanofi. Though this deal was long in the making, only time will tell whether shareholders on both sides of the deal really benefit.

6 Generic Products That Are Just As Good

The Deal
Sanofi-Aventis agreed to pay $74 a share in cash up front for Genzyme, a price that on its own virtually matches the all-time high set back in 2008. At that price, Sanofi is paying over four-times trailing revenue and over 26-times trailing EBITDA - a pretty generous premium compared to larger biotechs like Amgen (Nasdaq:AMGN) and Gilead (Nasdaq:GILD) as well as other growth names like Celgene (Nasdaq:CELG).

In response to charges of opportunism from Genzyme's management, Sanofi agreed to sweeten the pot with so-called contingent value rights (CVR). If Genzyme's business reaches certain milestones after the deal, Genzyme shareholders will get additional payments. There are six different hurdles laid out for Genzyme, worth up to $14 per share in total (or about $3.8 billion), but only the first three (production levels for Cerezyme, approval of Lemtrada and Lemtrada sales in excess of $400 million in certain territories) seem highly likely to be reached. If those three are reached, it will cost Sanofi about $4 per Genzyme share, while the remaining hurdles are all tied to ever-higher levels of sales.

The Logic of the Deal
Sanofi-Aventis is clearly hoping that this deal will stabilize the business as the company transitions through some severe patent-related revenue declines. While a resolution of Genzyme's manufacturing issues and the sales of products like Lumizyme and other drugs will help, Sanofi is also clearly banking on the synergies that are available in combining two large drug companies and firing suddenly redundant workers. Moreover, it is fair to assume that recent pipeline failures at Sanofi had to apply some pressure to management to find plugs for the new holes in the future revenue model.

There is certainly logic to a sale on the Genzyme side as well. Genzyme is facing more competition than ever before, with Shire (Nasdaq:SHPGY) and Protalix (NYSE:PLX) / Pfizer (NYSE:PFE) challenging the company in Gaucher disease, and Shire, Amgen and Abbott (NYSE:ABT) becoming more formidable in nephrology.

More worrisome than that, though, is the regulatory and reimbursement environment. The FDA has clearly become much more difficult to deal with and much more safety-conscious, and that could be a threat to a company that focuses on very rare diseases where regulators have in the past been less strict on safety due to a lack of treatment alternatives. What's more, as health care costs become increasingly problematic for payors, it is fair to wonder if these rare and orphan drug indications can continue to enjoy such high levels of reimbursement as in the past.

Danger and Opportunity
Sanofi may find that this deal never lives up to its promise. Roche (Nasdaq:RHHBY) has had mixed success with its acquisition of Genentech and other combinations between Big Pharma and Big Biotech have not really worked as well as the buyer had hoped. What's more, Sanofi may find that Genzyme does not really solve its own pipeline woes, as promising drugs like mipomersen (partnered with Isis Pharmaceuticals (Nasdaq:ISIS) could fall victim to a safety-obsessed FDA.

The Bottom Line
Although it is understandable to see how Sanofi felt they had to make strong moves to respond to investor concerns about growth and profit sustainability, the company will have its work cut out in making this deal a winner for its shareholders. Conversely, Genzyme shareholders should give some kudos to their management team for striking a rather hard bargain with a buyer that really felt it needed to seal a deal. (This high-risk strategy attempts to profit from price discrepancies that arise during acquisitions. See Trade Takeover Stocks With Merger Arbitrage.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    5 Cheap Dividend Stocks for a Bear Market

    Here are five stocks that pay safe dividends and should be at least somewhat resilient to a bear market.
  2. Investing

    How to Win More by Losing Less in Today’s Markets

    The further you fall, the harder it is to climb back up. It’s a universal truth that is painfully apparent in the investing world.
  3. Fundamental Analysis

    Use Options Data To Predict Stock Market Direction

    Options market trading data can provide important insights about the direction of stocks and the overall market. Here’s how to track it.
  4. Stock Analysis

    2 Oil Stocks to Buy Right Now (PSX,TSO)

    Can these two oil stocks buck the trend?
  5. Investing News

    What Alcoa’s (AA) Breakup Means for Investors

    Alcoa plans to split into two companies. Is this a bullish catalyst for investors?
  6. Stock Analysis

    Top 3 Stocks for the Coming Holiday Season

    If you want to buck the bear market trend by going long on consumer stocks, these three might be your best bets.
  7. Investing News

    Could a Rate Hike Send Stocks Higher?

    A rate hike would certainly alter the investment scene, but would it be for the better or worse?
  8. Investing News

    Corporate Bonds or Stocks: Which is Better Now?

    With market volatility high, you may think it is time to run for corporate bonds instead of stocks. Before you do take a deeper look into which is better.
  9. Mutual Funds & ETFs

    Using Short ETFs to Battle a Down Market

    Instead of selling your stocks to get gains, consider a short selling strategy, specifically one that uses short ETFs that help manage the risk.
  10. Investing Basics

    How to Diversify with International Stocks

    Diversifying with international stocks can benefit most portfolios, but beware of country risk.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!